volume 2, issue 8, PS406 2007
DOI: 10.1097/01.jto.0000283284.66317.c1
View full text
|
|
Share

Abstract: Background: Zoledronic acid has been shown to significantly reduce the risk of skeletal-related events (SREs) such as pathologic fractures in patients with bone metastases from solid tumors. Exploratory analyses have suggested that fractures correlate with reduced survival in patients with malignant bone disease. Moreover, increased risks for skeletal morbidity and death have been reported in patients with bone metastases and high levels of N-telopeptide of type I collagen (NTX) compared with patients with low…

Expand abstract

Search citation statements

Order By: Relevance

Citation Types

0
0
0

Paper Sections

0
0
0
0
0

Publication Types

0
0
0
0

Relationship

0
0

Authors

Journals